Yf-Vax Market Report 2026

Yf-Vax Market Overview

• The Yf-Vax market growth in the historic period has been driven by yellow fever endemic regions, international travel requirements • Market expansion is supported by increasing global travel, climate driven mosquito spread • Growth Driver: Rising Awareness of Vector-Borne Diseases Fuels Growth in YF-Vax Market • North America was the largest region in 2025 and Asia Pacific is the fastest growing region.

What Is Covered Under Yf-Vax Market?

YF-Vax is a live-attenuated vaccine designed to provide long-lasting protection against yellow fever, a potentially severe viral disease spread by infected mosquitoes, and is commonly recommended for travelers and residents in endemic areas. The main types of yf-vax are live attenuated vaccines, fractional dose vaccines. Live attenuated vaccines are a type of vaccine that contains live, but weakened, forms of the virus or bacteria that cause the disease. The various transmission types include sylvatic yellow fever, intermediate yellow fever, urban yellow fever. These are distributed through various distribution channels such as hospitals, retail pharmacies, government health programs and are used by various end users such as adult, geriatric, pediatric.

What Is The Yf-Vax Market Growth Forecast?

The yf-vax market size is expected to see strong growth in the next few years. It will grow to $9.81 million in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to increasing global travel, climate driven mosquito spread, expanded immunization coverage, rising outbreak preparedness funding, public health surveillance growth. Major trends in the forecast period include rising demand for travel vaccination, government led immunization programs, continued use of live attenuated vaccines, focus on endemic disease prevention, stockpiling for outbreak preparedness.

What Are The Drivers Of The Yf-Vax Market?

The increasing awareness of vector-borne diseases is expected to propel the growth of the YF-Vax market going forward. Vector-borne diseases are infectious diseases transmitted to humans and animals through the bite of infected arthropods, such as mosquitoes, ticks, and fleas, carrying pathogens such as viruses, bacteria, or parasites, leading to illnesses such as malaria, dengue, and Lyme disease. The rise in the prevalence of vector-borne diseases (VBDs) is due to climate change, urbanization, increased global travel, and expanding mosquito populations, leading to more outbreaks being reported. YF-Vax effectively prevents yellow fever, a vector-borne disease, by stimulating the immune system to produce antibodies, providing long-lasting protection against the virus transmitted by infected mosquitoes. For instance, in March 2024, according to the World Organization for Animal Health, a France-based intergovernmental organization, from 2023 to March 2024, vector-borne diseases caused 2,422 outbreaks in 28 countries, with Europe reporting 697 outbreaks. Therefore, increasing awareness of vector-borne diseases is driving growth in the YF-Vax industry. The rise in healthcare spending is expected to propel the growth of the Yf-Vax market going forward. Healthcare spending is attributed to aging population, advancements in medical technology, rising prevalence of chronic diseases, and increased demand for healthcare services. YF-VAX, by providing effective yellow fever prevention, helps reduce healthcare expenditure by minimizing the costs associated with treating severe infections, hospitalizations, and outbreak management. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, between 2022 and 2023, healthcare spending in the UK increased by 5.6% compared with growth of 0.9% in 2022. The UK healthcare expenditure in UK healthcare expenditure was around $317.63 billion (£292 billion) in 2023. Therefore, rise in healthcare spending is driving the growth of the Yf-Vax industry. The rising demand for international travel is expected to propel the growth of the Yf-Vax market going forward. International travel refers to traveling from one country to another, crossing borders for purposes such as tourism, business, education, visiting family, or other personal reasons. Rising demand for international travel is due to increasing disposable incomes globally, enabling more people to spend on leisure activities such as travel abroad. International travel enhances the YF-Vax market by increasing the need for preventive vaccination among travelers visiting yellow fever–endemic regions. It drives vaccine uptake by creating mandatory vaccination requirements for entry, ensuring protection against outbreaks and supporting global public health efforts. For instance, in June 2025, according to FREETOUR.com, a Switzerland-based travel services company, UK residents made over 90 million outbound trips in 2024 and are projected to make over 92 million outbound trips and receive 43.4 million international visitors in 2025. Therefore, the rising demand for international travel is driving the growth of the Yf-Vax industry.

Key Players In The Global Yf-Vax Market

Major companies operating in the yf-vax market are Sanofi S.A.

What Defines the Yf-Vax Market?

The yf-vax market consists of sales of vaccine syringes, pre-filled injection devices, and immunization kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Yf-Vax Market Report 2026?

The yf-vax market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the yf-vax industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.